Repligen Corp (RGEN) stock
RGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 7/30132% above fair value
$162.18−0.60 (-0.37%)
Close on Nov 17, 2026Market cap $10.37BP/E –Yield –
Repligen EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
Repligen's EV/EBITDA was 62.3× on Nov 11, 2026, against 113.9× a year earlier. Over the last 5 years it ranged from 28.7× to 236.6×, with a median of 61.7×.
EV/EBITDA at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 62.3× | −46.4 |
| 2025 | Dec 31, 2025 | 108.7× | +17.5 |
| 2024 | Dec 31, 2024 | 91.2× | +29.5 |
| 2023 | Dec 29, 2023 | 61.7× | +27.9 |
| 2022 | Dec 30, 2022 | 33.8× | −43.1 |
| 2021 | Dec 31, 2021 | 77.0× | −36.5 |
| 2020 | Dec 31, 2020 | 113.5× | +38.0 |
| 2019 | Dec 31, 2019 | 75.5× | +18.6 |
| 2018 | Dec 31, 2018 | 56.9× | −9.1 |
| 2017 | Dec 29, 2017 | 66.0× | +20.6 |
| 2016 | Dec 30, 2016 | 45.4× | −6.9 |
| 2015 | Dec 31, 2015 | 52.3× | +21.1 |
| 2014 | Dec 31, 2014 | 31.2× | −254.8 |
| 2013 | Dec 31, 2013 | 286.0× | +175.3 |
| 2012 | Dec 31, 2012 | 110.6× | +66.6 |
| 2011 | Dec 30, 2011 | 44.1× | – |
See a number that looks wrong?